868733-61-3

Basic information

• Product Name: 4-(2-chloropyridin-4-yloxy)-3-fluoro-phenylamine
• Synonyms: 4-(2-chloropyridin-4-yloxy)-3-fluoro-phenylamine
• CAS NO: 868733-61-3
• Molecular Weight: 238.649
• Mol File: 868733-61-3.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 4-(2-chloropyridin-4-yloxy)-3-fluoro-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-chloropyridin-4-yloxy)-3-fluoro-phenylamine(868733-61-3)
• EPA Substance Registry System: 4-(2-chloropyridin-4-yloxy)-3-fluoro-phenylamine(868733-61-3)

Safety Data

• Hazardous Substances Data: 868733-61-3(Hazardous Substances Data)

Upstream product

• 23056-36-2 2-chloro-4-nitropyridine 
• 399-96-2 4-amino-2-fluorophenol 
• 369-34-6 3,4-difluoronitrobenzene 
• 26452-80-2 2,4-dichloropyridine 

Downstream Products

• 1020173-11-8 4-(4-amino-2-fluorophenoxy)-N-benzyl-N-methylpyridin-2-amine 
• 868733-51-1 N-(4-(2-chloropyridin-4-yloxy)-3-fluorophenyl)acetamide 
• 1225278-30-7 3-fluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline 
• 1584220-10-9 N-(3-fluoro-4-((2-((3-((methylsulfonyl)methyl)phenyl)amino)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1584220-29-0 N-(4-((2-chloropyridin-4-yl)oxy)-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1020173-12-9 4-(4-amino-2-fluorophenoxy)-N-methylpyridin-2-amine 
• 1225283-31-7 4-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)-3-fluoroaniline 
• 868733-64-6 tert-Butyl 4-(2-chloropyridin-4-yloxy)-3-fluorophenylcarbamate 
• 868733-70-4 4-(4-amino-2-fluorophenoxy)-N-benzylpyridine-2-amine 

Relevant articles and documents

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.

PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER

Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.

Polysubstituted quinolone compounds, and preparation method and use thereof

The invention provides polysubstituted quinolone compounds, and a preparation method and a use thereof, and concretely provides a polysubstituted quinolone compound represented by formula I, and optical isomers, pharmaceutically acceptable salts or solvates thereof. All groups in the formula I are defined in the description. The quinolone compound has excellent c-Met inhibition activity, and can be used for treating c-Met activity or expression level corrected diseases.